Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study

The addition of quizartinib to standard chemotherapy was associated with significantly longer EFS and OS than placebo in patients with ND <i>FLT3</i>-ITD-negative AML.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-10-13
DOI
https://doi.org/10.1200/jco-25-01841
Citations
3
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
5.31
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study

Pau Montesinos, Olga Salamero, Rebeca Rodríguez‐Veiga, Mar Tormo et al.
3 citations
Journal of Clinical Oncology
Acute Myeloid Leukemia Research
5.31
article

Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study

Pau Montesinos, Olga Salamero, Rebeca Rodríguez‐Veiga, Mar Tormo, Eva Barragán, David Martínez‐Cuadrón, Marta Polo Zarzuela, José Ángel Raposo-Puglia, Antonio Martínez‐Francés, Sandra Suárez, María José Sayas-Lloris, Jorge Labrador, Raimundo García Boyero, Lorenzo Algarra, Rebeca Cuello, Manuel Barrios-García, Ignacio Casas-Avilés, Natalia Alonso, Matxalen Olivares, Josefina Serrano, Carmen Martínez‐Chamorro, Pilar Lloret Madrid, Bruno Paiva, José Luis López Lorenzo, Eduardo Rodríguez‐Arbolí, María Isabel Gómez-Roncero, Juan Bergua, María‐Belén Vídriales, Irene Sánchez‐Vadillo, Víctor Noriega, Teresa Bernal, Mercedes Colorado, Blanca Boluda, Pilar Herrera, Carmen Chillón, Rosa María Ayala, Carmen Botella, Alfonso Madridejos Fernández, María Calbacho, Susana Vives, María Solé Rodriguez, Marı́a José Calasanz, María‐José Sánchez, Juan Antonio López, Bernardo Javier González González, M Carmen Mateos, María Teresa Olave, Olga Arce, Carlos Rodríguez‐Medina, Lourdes Cuevas
article en
3 citations

Abstract

The addition of quizartinib to standard chemotherapy was associated with significantly longer EFS and OS than placebo in patients with ND <i>FLT3</i>-ITD-negative AML.

Journal of Clinical OncologyVol. 44(1)
Hebron University (PS), Universidade de Santiago de Compostela (ES), Hospital Universitario de Canarias (ES), Hospital Universitario La Paz (ES), University Hospital Complex Of Vigo (ES), Hospital Clínico San Carlos (ES), Hospital Universitari i Politècnic La Fe (ES), Josep Carreras Leukaemia Research Institute (ES), Hospital de Basurto (ES), Complejo Hospitalario Universitario de Santiago (ES), Hospital Universitario de Gran Canaria Doctor Negrín (ES), Hospital Universitario 12 De Octubre (ES), Hospital Txagorritxu (ES), Hospital Regional Universitario de Málaga (ES), Hospital Universitario Araba (ES), Hospital Universitario Quirónsalud Madrid (ES), Hospital San Pedro de Alcántara (ES), Instituto de Investigación Marqués de Valdecilla (ES), Hospital Universitario de Burgos (ES), Hospital de Galdakao (ES), Navarrabiomed (ES), Complejo Hospitalario de Jaén (ES), Hospital Universitario Reina Sofía (ES), Hospital General Universitari de Castelló (ES), Hospital Universitario Doctor Peset (ES), Vall d'Hebron Hospital Universitari (ES), Hospital Juan Ramón Jiménez (ES), Hospital Universitario Fundación Jiménez Díaz (ES), Instituto de Biomedicina de Sevilla (ES), Instituto de Investigación Biomédica de Salamanca (ES), Clinica Universidad de Navarra (ES), Hospital Clínico Universitario Lozano Blesa (ES), Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (ES), Hospital General Universitario de Alicante Doctor Balmis (ES), Complexo Hospitalario Universitario A Coruña (ES), Hospital Universitario Puerta del Mar (ES), Hospital Universitario Lucus Augusti (ES), Hospital General Universitario de Albacete (ES), Santa Lucía University General Hospital (ES), Instituto de Investigación Sanitaria de Santiago (ES), Hospital Universitario Virgen del Rocío (ES), Hospital Universitari Germans Trias i Pujol (ES), Hospital Clínico Universitario Virgen de la Victoria (ES), Hospital Clínico Universitario de Valladolid (ES), INCLIVA Health Research Institute (ES), Hospital Universitario Ramón y Cajal (ES), Complejo Hospitalario Universitario de Toledo (ES), Instituto de Investigación Sanitaria del Principado de Asturias (ES), Universidad de Navarra (ES)
Openalex Percentile: Top 4%
Acute Myeloid Leukemia Research
5.31
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.